Mounjaro and Cysts: What the Clinical Evidence Actually Shows

What the SURMOUNT trial programme found, and what it didn't

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and followed them for 72 weeks across multiple tirzepatide doses. The adverse event data collected across that programme is extensive. Cyst formation (whether ovarian, sebaceous, renal or any other category) was not identified as a treatment-related adverse event. This matters, because SURMOUNT captured a broad range of reported symptoms and was large enough to surface even uncommon effects.

What SURMOUNT did identify clearly was a gastrointestinal side-effect profile: nausea, vomiting, diarrhoea and constipation were the most common complaints, typically emerging after starting treatment or stepping up a dose and settling within days to a couple of weeks for most participants. The NHS tirzepatide medicines page reflects this same profile and lists no cyst-related effects.

There is one caveat worth noting: gallbladder problems, including gallstones, carry a small but recognised risk with GLP-1 class medicines. Gallstones are sometimes loosely described by patients as cysts, so if that is the overlap you are thinking about, it is worth raising your gallbladder history explicitly during your consultation. Rapid weight loss of any kind can increase the likelihood of gallstone formation, and your prescriber will factor that in.

Mounjaro, PCOS and ovarian cysts, what emerging evidence suggests

Polycystic ovary syndrome is one of the most common reasons people ask about Mounjaro and cysts specifically. PCOS involves hormonal dysregulation that can be worsened by excess weight, and many people with PCOS find weight management genuinely difficult. Tirzepatide's mechanism (acting on both the GIP and GLP-1 receptors to reduce appetite, slow gastric emptying and improve insulin sensitivity) has attracted real scientific interest in the PCOS context.

Early research and case series suggest that weight loss supported by GLP-1 class medicines can improve some hormonal markers associated with PCOS, including insulin resistance and androgen levels. Reduced insulin resistance in particular is meaningful, because high insulin drives much of the hormonal disruption in PCOS. However, tirzepatide does not have a specific PCOS licence, and the evidence base for this use is still developing. It would be an overstatement to say Mounjaro treats PCOS; it is more accurate to say that the weight loss it supports may ease some of its features for some people.

Ovarian cysts that are incidental and unrelated to PCOS are a different matter. If you have a known ovarian cyst, that history should be disclosed during your consultation, and our guide to Mounjaro and cystitis is also worth reading if you have a history of urinary tract or pelvic conditions that your prescriber should know about. There is no mechanism by which tirzepatide is expected to provoke cyst growth, but your prescriber should know your full picture.

When to have a cyst checked, a practical habit worth keeping

Starting any new medicine is a reasonable moment to set a simple baseline habit: once a month, take sixty seconds to note any new lumps, swellings or changes you've noticed anywhere on your body. It costs nothing and means you're not trying to remember whether something was there before you started treatment. If something new appears, your GP is the right first call, not to attribute it to Mounjaro, but to assess it on its own terms.

The MHRA's Yellow Card scheme exists precisely for situations where you suspect a medicine may be connected to something unexpected. You can report a suspected side effect via the Yellow Card service even if you're not certain; the data is valuable to regulators building the long-term safety picture for tirzepatide, which still carries a Black Triangle status (▼) indicating that additional monitoring is in place.

If you're curious about blood markers your prescriber might track during treatment, the guide to Mounjaro and blood tests explains what clinical monitoring during treatment typically involves. For a broader look at how tirzepatide works and who it is licensed for, the Mounjaro overview page covers the full picture. And if you're weighing up treatment options more generally, the weight-loss treatment overview is a good place to compare what's available through a UK-registered service.

Disclosing existing conditions before treatment, why it matters

Mounjaro is a prescription-only medicine, which means suitability is determined by a GPhC-registered prescriber who reviews your individual health history, not a checklist. Cysts or cyst-related conditions (whether active, resolved or surgically managed) are exactly the kind of detail that belongs in that conversation. A history of renal cysts, hepatic cysts, ovarian cysts or any other variety doesn't automatically disqualify you from treatment, but it helps the prescriber make a fully informed decision and identify anything that warrants monitoring, including skin-related changes such as those covered in our overview of tirzepatide and rosacea for anyone with a pre-existing skin condition.

At nume, every consultation is reviewed by a real clinician on the same day. There are no algorithms making approval decisions. If you have questions about a specific condition and how it might interact with tirzepatide, our prescribers are the right people to ask, and the consultation is free. The about us page explains how our clinical team is structured, and our lead prescriber's profile sets out the clinical oversight behind every decision.

For anyone exploring the cost side of private treatment, the guide to Mounjaro pricing in the UK gives honest context on what private treatment involves financially. When you're ready, you can start your free consultation and have your questions answered by a prescriber who has read your full history.